Sponsor Ad

August 4   2PM ET
Open Source Software:
Due Diligence in M&A


and gain insight
by viewing
earlier webinars

They are available at
CLE available in many states.

After Cuozzo:
Litigation at the PTAB, District Court, and
the Federal Circuit

Willfulness and
Enhanced Damages
After Halo

Readying a Patent Portfolio
for Sale

Internet of Things:
Standards, Licensing,
or Litigation?

New EU Trade Secrets Directive

Nuts & Bolts of
Registering Copyright on Software
Copyright on Software:
What's Covered
and What's Not?

Federal Trade Secret Law: 
Getting It Right Early  

Redundant Grounds in Post-Grant Proceedings
New PTAB Trial Rules
First Response to Trade Secret Theft
Lexmark: Licensing After the En Banc Decision

Extraterritorial Damages
After Carnegie Mellon

 Conflicts of Interest in
Patent Prosecution After
Maling v. Finnegan

 Insider Threat:  
Employee Mobility & 
Trade Secrets
High Tech, Double Patenting, and Ex Parte Reexam
  Patent Prosecution with
an Eye to the PTAB

Safeguarding GUIs:
Best Practices
Using Multiple Layers of IP
For a list of additional archived webinars, 
please visit

IPO IP Chat Channel Webinar


Wednesday Aug 10  2PM ET

Life Science
Thursday August 11  2PM ET
The Supreme Court's recent decision not to grant certiorari in
Ariosa v. Sequenom was a sharp disappointment to many inventors and patent owners who had hoped the Court would revisit and clarify its views on patent eligibility after its decisions in  Mayo and Alice. But that was not to be. As a result, the two industries most wounded by  Mayo and  Alice -- life sciences and computer software -- must look for paths ahead without any reprieve from the Justices. Recent Section 101 cases from the Federal Circuit and ex parte PTAB decisions can serve as signposts for both the life sciences and software industries. Each of our industry-specific panels is made up of a technically-savvy in-house counsel and two top law firm patent prosecutors. They will discuss cases such as:
  • Rapid Litigation v. CellzDirect, where in early July, the Federal Circuit panel reversed a district court's holding that claims to a method of isolating and preserving liver cells were patent-ineligible. The appellate court held that the claims did not encompass a judicial exception (step one of the Mayo/Alice analysis). The same kind of analysis helped save patents involving self-referential software databases in Enfish v. Microsoft this spring.  
  • Bascom v. AT&T, where in June the Federal Circuit reversed a district court's finding that Bascom's patent for filtering internet content failed step two of the Mayo/Alice test. The Federal Circuit stated that "the inventive concept inquiry requires more than recognizing that each claim element, by itself, was known in the art. . . an inventive concept can be found in the non-conventional and non-generic arrangement of known, conventional pieces." Life science experts believe this finding can also help life science patents.
Our panelists will give specific tips for drafting and prosecuting patents in their industries to avoid Section 101 rejections, resulting in patents that will withstand patent-eligibility attacks in litigation. The life science webinar will include discussion of both therapeutics and diagnostics, and the software webinar will include discussion of several recent useful ex parte PTAB decisions that overturned examiners Section 101 rejections.
August 10
Michelle Macartney i s a Senior IP Attorney in both the Prosecution and Acquisitions groups at Intellectual Ventures. Michelle's technical expertise is in the software and wireless/telecom areas. She has handled over 20 post-grant matters in front of the PTAB. 
Stephen Durant is a shareholder at Schwegman, Lundberg & Woessner. Steve is a patent prosecutor and IP strategist in technologies including Internet and database software and wired and wireless telecommunications. He is Co-Editor of
Electronics and Software Patents: Law and Practice (Third Edition 2012), published by BNA.
Amir Penn is a shareholder of Brinks Gilson Lione. He has substantial experience prosecuting patents, drafting opinions, and managing IP rights in the fields of software-related technology, printer technology, image processing, and wireless communications.
August 11

Deborah Martin  is Assistant General Counsel at Pfizer.  She leads a team of patent attorneys in the US and Europe responsible for the patent portfolios and IP strategy for biotherapeutics in the research units of ImmunoOncology, Inflammation, Rare Diseases, Neuroscience, and CVMET as well as diligence support for licensing, acquisitions, and R&D collaborations.  She holds a PhD in physiological sciences.
Christopher Jeffers  is a member of Mintz Levin Cohn Ferris Glovsky and Popeo. Chris helps life science clients with IP counsel involving technologies such as campanion diagnostics, next generation sequencing, arrays, cell therapy, and plant mutation. Chris is the former General Counsel of Alba Therapeutics, and serves as outside Chief Patent Counsel to a number of small and mid-sized life science companies. He holds a PhD in biochemistry and biophysics.
Warren Woessner is a founding partner and chair of the biopharma group at Schwegman Lundberg & Woessner. Warren works on solutions for complex prosecution problems. He holds a Ph.D. in organic chemistry and is the author of the blog Patents4Life.  
Intellectual Property Owners Association's
     one-hour webinars on current topics in IP,
hosted by Pamela Sherrid,
former editor of IP Law & Business magazine 


$135 per user per webinar

 Academic and government discount available 

through written request to meetings@ipo.org  


To register, please click to



Continuing Legal Education Credit (CLE) is available.

IPO is applying for CLE in a limited number of states. Visit www.ipo.org/IPChatChannel for current CLE information.